Cargando…

Efficacy of Recombinant Human Endostatin plus Neoadjuvant Chemotherapy for Osteosarcoma and Its Influence on Serum VEGF and MMP-9 Levels

OBJECTIVE: To investigate the efficacy of recombinant human endostatin (rh-Endo) plus neoadjuvant chemotherapy (NACT) for osteosarcoma (OSA) and its influence on serum vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9). METHODS: The case data of 141 OSA patients present...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sui, Wei, Lin, Guanghui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985508/ https://www.ncbi.nlm.nih.gov/pubmed/36880008 http://dx.doi.org/10.1155/2023/8161683

Ejemplares similares

Case Report: Recombinant Human Endostatin Plus Chemotherapy for Epidermal Growth Factor Receptor-Negative Miliary Lung Adenocarcinoma
por: Zhu, Jian, et al.
Publicado: (2022)

Elevated ratio of MMP2/MMP9 activity is associated with poor response to chemotherapy in osteosarcoma
por: Kunz, Pierre, et al.
Publicado: (2016)

Continuous intravenous infusion of recombinant human endostatin using infusion pump plus chemotherapy in non-small cell lung cancer
por: Qin, Zhi-Quan, et al.
Publicado: (2022)

Safety and efficacy of nivolumab plus recombinant human endostatin in previously treated advanced non-small-cell lung cancer
por: Lv, Weize, et al.
Publicado: (2022)

Efficacy of Neoadjuvant Chemotherapy plus Limb-Sparing Surgery for Osteosarcoma and Its Impact on Long-Term Quality of Life
por: Jing, Shixia, et al.
Publicado: (2022)

Clinical effects of cisplatin plus recombinant human endostatin (rh-endostatin) intratumoral injection on malignant central airway obstruction: a retrospective analysis of 319 cases
por: Zhou, Yunzhi, et al.
Publicado: (2021)

Efficacy and safety of rh‐endostatin (Endostar) combined with pemetrexed/cisplatin followed by rh‐endostatin plus pemetrexed maintenance in non‐small cell lung cancer: A retrospective comparison with standard chemotherapy
por: Zhou, Shengyu, et al.
Publicado: (2018)

Neoadjuvant multidrug chemotherapy including High-Dose Methotrexate modifies VEGF expression in Osteosarcoma: an immunohistochemical analysis
por: Rossi, Barbara, et al.
Publicado: (2010)

Efficacy and safety of extended use of platinum-based doublet chemotherapy plus endostatin in patients with advanced nonsmall cell lung cancer
por: Hu, Weiheng, et al.
Publicado: (2016)

Endostatin inhibits VEGF-A induced osteoclastic bone resorption in vitro
por: Sipola, Annina, et al.
Publicado: (2006)

Antiangiogenic effects of recombinant human endostatin in lung cancers
por: He, Lang, et al.
Publicado: (2018)

MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study
por: Tabouret, Emeline, et al.
Publicado: (2016)

Perioperative rh-endostatin with chemotherapy improves the survival of conventional osteosarcoma patients: a prospective non-randomized controlled study
por: Xu, Hairong, et al.
Publicado: (2019)

Recombined humanized endostatin (Endostar) combined with chemotherapy for advanced bone and soft tissue sarcomas in stage IV
por: Xing, Peipei, et al.
Publicado: (2016)

Recombinant human endostatin combined with chemotherapy for advanced squamous cell lung cancer: a meta-analysis
por: Feng, Li, et al.
Publicado: (2021)

The Plasma Concentration of D-Dimer is Associated with Neoadjuvant-Chemotherapy Efficacy and the Prognosis in Osteosarcoma
por: Huang, Yujing, et al.
Publicado: (2021)

Low Mmp 9 and VEGF levels predict good oncologic outcome in mid and low rectal cancer patients with neoadjuvant chemoradiation
por: Kurt, Atilla, et al.
Publicado: (2012)

Monitoring early responses to neoadjuvant chemotherapy and the factors affecting neoadjuvant chemotherapy responses in primary osteosarcoma
por: Yu, Hong, et al.
Publicado: (2023)

Interactions between Endostatin and Vascular Endothelial Growth Factor (VEGF) and Inhibition of Choroidal Neovascularization
por: Wang, Xun, et al.
Publicado: (2007)

Endostatin and Cancer Therapy: A Novel Potential Alternative to Anti-VEGF Monoclonal Antibodies
por: Méndez-Valdés, Gabriel, et al.
Publicado: (2023)

Relevance of EGFR Between Serum VEGF and MMP-9 in Primary Hepatocellular Carcinoma Patients with Transarterial Chemoembolization
por: Cao, Shengya, et al.
Publicado: (2020)

Effect of Moxibustion on the Serum Levels of MMP-1, MMP-3, and VEGF in Patients with Rheumatoid Arthritis
por: Yu, Zeyun, et al.
Publicado: (2020)

Endostatin in the pancreas
por: Wigmore, S J
Publicado: (2005)

Serum Endostatin Levels in Oral Squamous Cell Carcinoma
por: Mardani, Maryam, et al.
Publicado: (2018)

Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: efficacy and safety in a prospective, randomized, phase II study
por: Chen, Jianghao, et al.
Publicado: (2013)

Recombinant human endostatin in combination with CHOP regimen for peripheral T cell lymphoma
por: Zhang, Qunling, et al.
Publicado: (2016)

The accumulation of macrophages attenuates the effect of recombinant human endostatin on lung cancer
por: Liu, Yanyang, et al.
Publicado: (2016)

Recombinant human endostatin combined with radiotherapy inhibits colorectal cancer growth
por: Zhang, Ke, et al.
Publicado: (2017)

Current Status and Study Progress of Recombinant Human Endostatin in Cancer Treatment
por: Li, Kai, et al.
Publicado: (2018)

Predictive and prognostic value of Matrix metalloproteinase (MMP) - 9 in neoadjuvant chemotherapy for triple-negative breast cancer patients
por: Wang, Ruo-Xi, et al.
Publicado: (2018)

Detection of serum VEGF and MMP-9 levels by Luminex multiplexed assays in patients with breast infiltrative ductal carcinoma
por: ZHANG, JUNYING, et al.
Publicado: (2014)

Expression of MMP-9 and VEGF in Meningiomas and Their Correlation with Peritumoral Brain Edema
por: Reszec, Joanna, et al.
Publicado: (2015)

Immunotherapy combined with rh-endostatin improved clinical outcomes over immunotherapy plus chemotherapy for second-line treatment of advanced NSCLC
por: Huang, Hongxiang, et al.
Publicado: (2023)

The number of osteoclasts in a biopsy specimen can predict the efficacy of neoadjuvant chemotherapy for primary osteosarcoma
por: Araki, Yoshihiro, et al.
Publicado: (2021)

Comparisons of biophysical properties and bioactivities of mono-PEGylated endostatin and an endostatin analog
por: Wang, Shan, et al.
Publicado: (2016)

Reprograming the tumor immunologic microenvironment using neoadjuvant chemotherapy in osteosarcoma
por: Deng, Chuangzhong, et al.
Publicado: (2020)

Analysis of prognostic factors and histopathological response to neoadjuvant chemotherapy in osteosarcoma
por: Erdoğan, Furkan, et al.
Publicado: (2023)

A high risk of osteosarcoma in individuals who are homozygous for the p.D104N in endostatin
por: Bi, Wen-Zhi, et al.
Publicado: (2015)

Serum levels of VEGF and MCSF in HER2+ / HER2- breast cancer patients with metronomic neoadjuvant chemotherapy
por: Arai, Roberto J., et al.
Publicado: (2018)

Chemotherapy Combined With Recombinant Human Endostatin (Endostar) Significantly Improves the Progression-Free Survival of Stage IV Soft Tissue Sarcomas
por: Liao, Zhichao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bafcf6o3ga0hoshm6oucolj92a